Trevena, Inc. (TRVN)

Trevena, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:TRVN)

Trevena, Inc. (NASDAQ:TRVN – Free Report) – HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for Trevena in a research report issued to clients and investors on Thursday, May 16th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will earn ($0.37) per share for the quarter, down from their previous forecast of ($0.30). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Trevena’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Trevena’s Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.29) EPS, FY2025 earnings at ($0.79) EPS, FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.90) EPS. Trevena (NASDAQ:TRVN – Get Free Report) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.01. The firm had revenue of $0.02 million during the quarter. Separately, StockNews.com began coverage on Trevena in a research report on Thursday. They issued a “sell” rating on the stock. Read Our Latest Research Report on Trevena Trevena Price Performance NASDAQ TRVN opened at $0.40 on Monday. The business’s fifty day moving average is $0.43 and its 200 day moving average is $0.56. The company has a market capitalization of $7.42 million, a PE ratio of -0.15 and a beta of 1.11. Trevena has a fifty-two week low of $0.30 and a fifty-two week high of $1.35. The company has a debt-to-equity ratio of 8.35, a quick ratio of 4.66 and a current ratio of 3.60. Institutional Trading of Trevena An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC bought a new position in shares of Trevena, Inc. (NASDAQ:TRVN – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena as of its most recent filing with the Securities and Exchange Commission (SEC). 13.56% of the stock is currently owned by institutional investors. Trevena Company Profile (Get Free Report) Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. See Also Five stocks we like better than Trevena What is MarketRank? How to Use it MarketBeat Week in Review – 5/13 – 5/17 What is the Euro STOXX 50 Index? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Ways To Invest In Coffee, Other Than Drinking It Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook